UNSPSC 51241002: Triethanolamine polypeptide oleate

This classification denotes an aural eardrop preparation.

UNSPSC 51241002 Triethanolamine polypeptide oleate is a Commodity code that in recent state and local solicitations covers pharmaceutical products, drug-related supplies, and over-the-counter health items rather than the specific chemical compound its name suggests. State and local governments procuring under this code are acquiring naloxone, drug deactivation systems, generic pharmaceuticals, and OTC products through centralized purchasing vehicles and individual county health departments. Issuing bodies include county health agencies (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon and Minnesota). The code captures both direct commodity purchases and exploratory requests for information that precede formal pharmaceutical supplier contracts.

Recent activity shows geographic spread across Florida, Texas, and the Upper Midwest. Representative solicitations include Seminole County's IFB60459723LAS (posted June 30, 2026; response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026; response due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products through authorized wholesalers. The MMCAP solicitation applies pricing weights of 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on compliance, EDI capability, and administrative fee agreement, with contract terms of two years for new vendors. Awarded vendors under the MMCAP agreement are required to maintain insurance including $5,000,000 commercial general liability per occurrence and comply with FDA requirements and the Drug Supply Chain Security Act.